𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Combined androgen blockade with nonsteroidal antiandrogens for advanced prostate cancer: a systematic review

✍ Scribed by Brian Schmitt; Timothy J Wilt; Paul F Schellhammer; Vincenzo DeMasi; Oliver Sartor; E.David Crawford; Charles L Bennett

Book ID
117263488
Publisher
Elsevier Science
Year
2001
Tongue
English
Weight
463 KB
Volume
57
Category
Article
ISSN
0090-4295

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Monotherapy versus combined androgen blo
Monotherapy versus combined androgen blockade in patients with advanced prostate cancer
✍ Abelardo Errejon; E. David Crawford πŸ“‚ Article πŸ“… 2002 πŸ› John Wiley and Sons 🌐 English βš– 33 KB

Despite a number of large randomized clinical trials, there still is uncertainty regarding the value of maximal androgen blockade in the treatment of patients with advanced prostate carcinoma. In the referenced article, the authors provide a very comprehensive review of the literature concerning one

Systematic review and meta-analysis of m
Systematic review and meta-analysis of monotherapy compared with combined androgen blockade for patients with advanced prostate carcinoma
✍ David J. Samson; Jerome Seidenfeld; Brian Schmitt; Vic Hasselblad; Peter C. Albe πŸ“‚ Article πŸ“… 2002 πŸ› John Wiley and Sons 🌐 English βš– 131 KB πŸ‘ 1 views

## Abstract ## BACKGROUND The current systematic review and meta‐analysis compared monotherapy and combined androgen blockade in the treatment of men with advanced prostate carcinoma. Outcomes of interest included overall, cancer specific, and progression‐free survival; time to treatment failure;

Twenty years of controversy surrounding
Twenty years of controversy surrounding combined androgen blockade for advanced prostate cancer
✍ Judd W. Moul πŸ“‚ Article πŸ“… 2009 πŸ› John Wiley and Sons 🌐 English βš– 71 KB

The current issue of __Cancer__ includes a report on a concise, randomized controlled trial (RCT) with long‐term follow‐up that favors combined androgen blockade with bicalutamide versus lutenizing hormone‐releasing hormone monotherapy in Japanese men with locally advanced and metastatic prostate ca